Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CeNeRx BioPharma has announced plans to advance its lead candidate Tyrima into Phase II trials for the treatment of depression and anxiety.
Subscribe to our email newsletter
This milestone is based on the positive results of the Tyrima Phase I program reported earlier in 2008 and the recent completion of Pet brain imaging studies showing that Tyrima penetrates the central nervous system and exhibits excellent pharmacokinetic and pharmacodynamic properties.
The first Tyrima Phase II trial is a double-blind, placebo-controlled, multi-center study expected to enroll over 270 patients with major depressive disorder. The study is expected to start before the end of this quarter in 2008.
CeNeRx’s Tyrima is a selective and reversible member of a novel class of drugs known as RIMAs, or reversible inhibitors of monoamine oxidase A (MAO-A).
CeNeRx has worldwide rights to develop and commercialize Tyrima. This compound, which could be the first RIMA antidepressant available in the US market, has patent protection beyond 2027.